Newer antidepressants and the cytochrome P450 system

American Journal of Psychiatry

Volumn 153, Issue 3, 1996, Pages 311-320

  Nemeroff, Charles B ^a   Devane, C Lindsay ^b   Pollock, Bruce G ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450; DESIPRAMINE; FLUOXETINE; NEFAZODONE; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TERFENADINE; THEOPHYLLINE DERIVATIVE; TRIAZOLAM; VENLAFAXINE;

AEROBIC METABOLISM; CLINICAL PRACTICE; DEPRESSION; ENDOPLASMIC RETICULUM; FATTY ACID METABOLISM; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; REVIEW; STEROID ANALYSIS;

EID: 0029976064     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.3.311     Document Type: Review

References (101)

1. Brøsen K: Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18:220-239
2. Pollock BG: Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry 1994; 2:204-213
3. Meyer UA, Zanger UM, Grant D, Blum M: Genetic polymorphisms of drug metabolism. Advances in Drug Res 1990; 19: 197-241
4. Brøsen K: The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 1993; 71:1002-1009
5. DeVane CL: Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994; 97(suppl 6A):13S-23S
6. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM: Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors (abstract PI-71). Clin Pharmacol Ther 1994; 55:141
7. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT: The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992; 33:521-523
8. van Harten J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24:203-220
9. Eichelbaum M, Gross AS: The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Ther 1990; 46:377-394
10. Gonzalez FJ, Meyer UA: Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991; 50:233-238
11. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17:102-105
12. Relling MV, Evans WE, Fonne-Pfister R, Meyer UA: Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes. Cancer Res 1989; 49:68-71
13. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R: Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53:5121-5126
14. Gorski JC, Jones DR, Wrighton SA, Hall SD: Characterization of dextromethorphan N-demethylation by human liver microsomes: contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 48:173-182
15. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T: CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3:197-204
16. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M: Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993; 348:332-337
17. Jerling M, Lindstrom L, Bondesson U, Bertilsson L: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16:368-374
18. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K, Fukushima Y: Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995; 17:333-335
19. Brøsen K, Gram LF: Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36:537-547
20. Brøsen K, Skjelbo E: Fluoxetine and norfluoxetine are potent inhibitors of P450IID6: the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991; 32:136-137
21. Bluhm RE, Wilkinson GR, Shelton R, Branch RA: Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin Pharmacol Ther 1993; 53:89-95
22. Pollock BG, Mulsant BH, Sweet RA, Rosen J, Altieri LP, Perel JM: Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995; 31:327-331
23. Spina E, Ancione M, DiRosa AE, Meduri M, Caputi AP: Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 1992; 42:347-348
24. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34:262-265
25. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM: Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53:401-409
26. Smith DA, Jones BC: Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44:2089-2098
27. Guengerich FP: Human cytochrome P-450 enzymes. Life Sci 1992; 50:1471-1478
28. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengil JP, Lawsen MF, Kadlubar FF: Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2:116-127
29. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45:1211-1214
30. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33:1743-1752
31. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WR: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin drug interactions. Chem Res Toxicol 1992; 5:54-59
32. Smith DA: Species differences in metabolism and pharmacokinencs: are we close to an understanding? Drug Metab Rev 1991; 23:355-373
33. Knodell RG, Hall SD, Wilkinson GR, Guengerich FP: Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 1987; 241: 1112-1119
34. Newlands AJ, Smith DA, Jones BC, Hawksworth GM: Metabolism of non-steroidal anti-inflammatory drugs by cytochrome P450 2C (abstract). Br J Clin Pharmacol 1992; 34:152P
35. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA: Interethnic differences in genetic polymorphism of debrisoquin and mephenytom hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-408
36. Pollock BG, Perel JM, Kirshner M, Altieri LP, Yeager AL, Reynolds CF III: S-Mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol 1991; 40:609-611
37. Wilkinson GR, Guengerich FP, Branch RA: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989; 43:53-76
38. Jalil P: Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports (letter). J Neurol Neurosurg Psychiatry 1992; 55:412-413
39. Skjelbo E, Brøsen K: Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34:256-261
40. Guengerich FP: Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990; 3:363-371
41. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH: Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47:1969-1979
42. Murray M: P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992; 23:132-146
43. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP: Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993; 43:827-832
44. Bonnet P, Vandel S, Nezelof S, Sechter D, Bizouard P: Carbamazepine, fluvoxamine: is there a pharmacokinetic interaction? (letter). Therapie 1992; 47:165
45. Fleishaker JC, Hulst LK: A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994; 46:35-39
46. Greene DS, Dockens RC, Salazar DE, Barbhaiya RH: Coadmin-istration of nefazodone and benzodiazepines, I: pharmacokinetic assessment (abstract PI-74). Clin Pharmacol Ther 1994; 55:141
47. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS: Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52:479-486
48. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ: Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991; 50:10-15
49. Swims MP: Potential terfenadine-ftuoxetine interaction (letter). Ann Pharmacother 1993; 27:1404-1405
50. Joblin M, Ghose K: Possible interaction of sertraline with carbamazepine (letter). NZ Med J 1994; 107:43
51. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI: Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268: 1278-1283
52. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI: Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15:125-131
53. Bergstrom RF, Peyton AL, Lemberger L: Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51:239-248
54. Vandel S, Bertschy G, Bonin B, Nezelof S, Francois TH, Vandel B, Sechter D, Bizovard P: Tricyclic antidepressant plasma levels after fluoxetine addition. Pharmacopsychiatry 1992; 25:202-207
55. Vaughan DA: Interaction of fluoxetine with tricyclic antidepressants (letter). Am J Psychiatry 1988; 145:1478
56. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ: Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991; 148:790-792
57. Tate JL: Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine (letter). Am J Psychiatry 1989; 146:399-400
58. Woods DJ, Coulter DM, Pillans P: Interaction of phenytoin and fluoxetine (letter). NZ Med J 1994; 107:19
59. Lemberger L, Rowe H. Bosomworth JC, Tenbarge JB, Bergstrom RF: The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988; 43:412-419
60. Gernaat HBPE, Van de Woude J, Touw DJ: Fluoxetine and parkinsonism in patients taking carbamazepine (letter). Am J Psychiatry 1991; 148:1604-1605
61. Pearson HJ: Interaction of fluoxetine with carbamazepine (letter). J Clin Psychiatry 1990; 51:126
62. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ: Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl) 1991; 104:323-327
63. Barros J, Asnis G: An interaction of sertraline and desipramine (letter). Am J Psychiatry 1993; 150:1751; correction, 1994; 151:300
64. Lydiard RB, Anton RF, Cunningham T: Interactions between sertraline and tricyclic antidepressants (letter). Am J Psychiatry 1993; 150:1125-1126
65. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14:90-98
66. Zussman BD, Davie CC, Fowles SE, Kumar R, Lang U, Wargenau M, Sourgens H: Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br J Clin Pharmacol 1995; 39:550-551
67. Alderman J, Greenbiatt DJ, Allison J, Preskorn S, Harrison W, Chung M: Desipramine pharmacokinetics with the selective serotonin reuptake inhibitors (SSRIs), paroxetine or sertraline, in New Research Program and Abstracts, 147th Annual Meeting of the American Psychiatric Association. Washington, DC, APA, 1994
68. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF: Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44:349-355
69. Preskorn SH: Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54(Sept suppl): 14-34
70. Reeves R: Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics 1995; 36:159-160
71. Diot P, Jonville AP, Gerard F, Bonneville M, Autret E, Breteau M, Lemarie E, Lavandier M: Possible interaction entre theophylline et fluvoxamine. Therapie 1991; 46:169-171
72. Sperber AD: Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991; 6:460-462
73. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H: Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14:279-281
74. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egan M, Elkashef A, Liboff S, Linnoila M: Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994; 14:340-343
75. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R: Fluvoxamine-tricyclic antidepressant interaction: an accidental finding. Eur J Clin Pharmacol 1991; 40:119-120
76. Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP: Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res 1993; 13:167-171
77. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP: Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15:243-246
78. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M: Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994; 56:471-476
79. Fritze J, Unsorg B, Lanczik M: Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991; 84:583-584
80. Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J, Shrivastava RK: A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 1991; 159: 394-398
81. Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL, Dessain EC, Itil TM, Lautin A: Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51 (Dec suppl B):28-33
82. Gregor KJ, Overhage JM, Coons SJ, McDonald RC: Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clin Ther 1994; 16:306-315
83. Reimhert FW, Chouinard G, Cohn CK, Cole JO, Itil TM, La-Pierre YD, Masco HL, Mendels J: Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51(Dec suppl B): 18-27
84. Reimherr FW, Byerley WF, Ward MF, Lebegue BJ, Wender PH: Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull 1988; 24:200-205
85. Stock AJ, Kofoed L: Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting. Am J Hosp Pharm 1994; 51:2279-2281
86. Bennie EH, Mullin JM, Martindale JJ: A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995; 56:229-237
87. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD: The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51:278-287
88. Nemeroff CB: Augmentation regimens for depression. J Clin Psychiatry 1991; 52(May suppl):21-27
89. Physician Drug and Diagnosis Audit (PDDA). Newtown, Pa, Scott-Levin Associates, a subsidiary of PMSI, January-December, 1994
90. Maskall DD, Lam RW: Increased plasma concentration of imipramine following augmentation with fluvoxamine (letter). Am J Psychiatry 1993; 150:1566
91. Tyndale RF, Kalow W, Inaba T: Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991; 31:655-660
92. Llerena A, Dahl ML, Ekqvist B, Bertilsson L: Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992; 14:261-264
93. Preskorn SH, Magnus RD: Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1994; 30:251-259
94. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T: Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348-355
95. Shader RI, Greenblatt DJ, von Moltke LL: Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994; 14: 375-376
96. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JGC: Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand Suppl 1989; 350:102-106
97. Andersen BB, Mikkelsen M, Vesterager A, Dam M, Kristensen HB, Pedersen B, Lund J, Mengel H: No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991; 10:201-204
98. Gidal BE, Anderson GD, Seaton TL, Miyoshi HR, Wilenksy AJ: Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther Drug Monit 1993; 15:405-409
99. Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F: Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993; 15:247-250
100. Lane RM: Carbamazepine and sertraline (letter). NZ Med J 1994; 107:209
101. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR: Terfenadine-ketoconazole interaction. JAMA 1993; 269:1513-1518